Allspring Global Investments Holdings LLC Sells 3,246 Shares of Biohaven Ltd. (NYSE:BHVN)

Allspring Global Investments Holdings LLC lowered its stake in shares of Biohaven Ltd. (NYSE:BHVNFree Report) by 27.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,542 shares of the company’s stock after selling 3,246 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Biohaven were worth $222,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. US Bancorp DE increased its position in shares of Biohaven by 19.1% in the 1st quarter. US Bancorp DE now owns 586 shares of the company’s stock valued at $70,000 after buying an additional 94 shares in the last quarter. Cetera Advisor Networks LLC bought a new stake in shares of Biohaven in the first quarter worth about $332,000. AlphaCrest Capital Management LLC acquired a new stake in shares of Biohaven during the first quarter worth about $344,000. BlackRock Inc. lifted its holdings in shares of Biohaven by 0.5% during the 1st quarter. BlackRock Inc. now owns 4,656,866 shares of the company’s stock valued at $552,163,000 after purchasing an additional 21,586 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Biohaven by 55.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 82,599 shares of the company’s stock valued at $9,794,000 after purchasing an additional 29,413 shares during the period. 89.60% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Irina Antonijevic sold 11,000 shares of the stock in a transaction that occurred on Friday, December 29th. The stock was sold at an average price of $41.79, for a total value of $459,690.00. Following the completion of the sale, the director now owns 2,535 shares of the company’s stock, valued at approximately $105,937.65. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 15.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Biohaven from $26.00 to $32.00 and gave the company an “overweight” rating in a research note on Monday, November 20th. Piper Sandler increased their target price on Biohaven from $29.00 to $36.00 and gave the stock an “overweight” rating in a report on Wednesday, November 15th. Robert W. Baird assumed coverage on Biohaven in a research note on Friday, December 8th. They issued an “outperform” rating and a $58.00 price target on the stock. Finally, HC Wainwright started coverage on Biohaven in a research report on Friday, December 22nd. They set a “buy” rating and a $50.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $39.17.

View Our Latest Research Report on Biohaven

Biohaven Trading Down 4.3 %

Shares of BHVN stock opened at $43.69 on Wednesday. The firm’s fifty day moving average price is $39.85 and its two-hundred day moving average price is $29.08. Biohaven Ltd. has a 1 year low of $12.35 and a 1 year high of $49.65. The firm has a market capitalization of $3.50 billion, a P/E ratio of -6.09 and a beta of 1.15.

Biohaven (NYSE:BHVNGet Free Report) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($1.50) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.17). As a group, equities research analysts forecast that Biohaven Ltd. will post -5.22 EPS for the current fiscal year.

About Biohaven

(Free Report)

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases.

Read More

Institutional Ownership by Quarter for Biohaven (NYSE:BHVN)

Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.